Endocrine, Metabolic & Immune Disorders-Drug Targets

(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Emilio Jirillo  
Universitá degli Studi di Bari
Dipartimento di Clinica Medica
Immunologia e Malattie Infettive
Sezione di Microbiologia e Immunologia
Piazza Giulio Cesare-Policlinico
Bari
Italy

Back

Incretin Based Therapies: Bone Protective Effects

Author(s): Marlene Chakhtoura and Sami T. Azar

Affiliation: Department of Internal Medicine, Division of Endocrinology and Metabolism, American University of Beirut-Medical Center, 3 Dag Hammarskjold Plaza, 8th floor, New York, NY 10017, USA.

Keywords: Dipeptidyl peptidase-4 inhibitors, glucagon like peptide -1 agonists, incretin therapy, osteoporosis, type 2 diabetes mellitus.

Abstract:

Type 2 Diabetes Mellitus (T2D) and osteoporosis have been found recently to be tightly correlated. In fact, T2D can result in bone loss through different mechanisms resulting in alteration of bone matrix and inhibition of bone formation. Fracture risk also increases significantly. New antidiabetic agents, dipeptidyl peptidase-4 inhibitors and glucagon like peptide -1 agonists have shown promise in many fields beyond glycemic control. Benefits on the skeletal system are multiple through direct stimulation of osteoblasts, inhibition of advanced glycation end products and inhibition of bone resorption. However, clinical evidence in humans is still not enough to allow definitive conclusions.

Reprint ePrint Rights & PermissionsPrintExport

Article Details

VOLUME: 13
ISSUE: 4
Page: [289 - 294]
Pages: 6
DOI: 10.2174/18715303113136660046